A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

BACKGROUND Early serous carcinomas predominate in the fimbria of women with BRCA mutations (BRCA+). An entity in non-neoplastic mucosa sharing several properties of early serous carcinomas--the "p53 signature"--has been described in the distal fallopian tube and proposed as a precursor to serous carcinomas. This study compared the prevalence of p53 signatures in ovarian cortical inclusion cysts (CICs) and fallopian tubes from BRCA+ women and explored their relationship. DESIGN All tissues from 75 completely excised ovaries and tubes obtained during prophylactic surgery were studied by conventional microscopy, immunostaining for p53, and in selected cases, gamma-H2AX (DNA damage). P53 signatures were defined as 12 or more consecutive p53-positive secretory cell nuclei. Their prevalence in fallopian tubes and CICs was recorded, compared to an existing database of consecutive women without a suspicion of BRCA+ or ovarian cancer, and correlated with the number of CICs. RESULTS Tubal p53 signatures were detected in 29 of 75 cases (38%); 20 of 30 (66%) signatures examined were gamma-H2AX-positive. One ovary contained a small gamma-H2AX negative p53 signature on the ovarian surface; no p53 signatures were identified in CICs. The prevalence of BRCA+ p53 tubal signatures was similar to that of women with unknown BRCA status (38 v 33%). Presence of p53 signatures did not correlate with number of CICs. CONCLUSIONS p53 signatures were common in the fallopian tubes of BRCA+ women, were not identified in CICs, and did not correlate with the latter. The tubal p53 signature merits serious consideration as an important early event in serous carcinogenesis in BRCA+ women.

[1]  A. Whittemore,et al.  Histopathology, FIGO Stage, and BRCA Mutation Status of Ovarian Cancers from the Gilda Radner Familial Ovarian Cancer Registry , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[3]  S. Tsao,et al.  Amplification and overexpression of Aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells , 2005, Molecular carcinogenesis.

[4]  P. Elton,et al.  Prophylactic oophorectomy , 1993, The Lancet.

[5]  Michel Nussenzweig,et al.  H2AX: the histone guardian of the genome. , 2004, DNA repair.

[6]  A. Monteiro,et al.  DNA damage response: Determining the fate of phosphorylated histone H2AX , 2006, Cancer biology & therapy.

[7]  Meenakshi Singh,et al.  Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries , 2007, Modern Pathology.

[8]  R. Gershoni-baruch,et al.  Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. , 2005, Gynecologic oncology.

[9]  J. Hayes,et al.  Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. , 2005, Molecular cell.

[10]  K. Naka,et al.  DNA damage tumor suppressor genes and genomic instability. , 2004, Current opinion in genetics & development.

[11]  J Gil,et al.  Ovarian dysplasia in prophylactic oophorectomy specimens , 1999, Cancer.

[12]  R. Scully,et al.  Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.

[13]  P. V. van Diest,et al.  Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study , 2004, Familial Cancer.

[14]  B. Karlan,et al.  BRCA-Mutation–Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? , 2005, Obstetrics and gynecology.

[15]  C. Mettlin,et al.  Age-specific ovarian cancer incidence rate patterns in the United States. , 2005, Gynecologic oncology.

[16]  O. Valenta,et al.  Gynecologic oncology , 1990 .

[17]  S. Selvaggi,et al.  Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament , 2009, Archives of pathology & laboratory medicine.

[18]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[19]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[20]  P. Kenemans,et al.  Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. , 2004, American journal of obstetrics and gynecology.

[21]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[22]  M. Wells,et al.  p53 protein expression in putative precursor lesions of epithelial ovarian cancer , 1995, Histopathology.

[23]  C. Eng,et al.  Molecular identification of latent precancers in histologically normal endometrium. , 2001, Cancer research.

[24]  Ross S Berkowitz,et al.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Colgan,et al.  Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.

[26]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[27]  W. Murdoch,et al.  Oxidative Damage to DNA of Ovarian Surface Epithelial Cells Affected by Ovulation: Carcinogenic Implication and Chemoprevention , 2004, Experimental biology and medicine.

[28]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.